Exogenous expression of Drp1 plays neuroprotective roles in the Alzheimer’s disease in the Aβ42 transgenic Drosophila model

Fengshou Lv¹, Xiaopeng Yang²*, Chuanju Cui³, Chunhe Su²

1 Department of Pathology, Henan Medical College, Zhengzhou, China, 2 Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 3 Department of Neurology, Zhengzhou First People’s Hospital, Zhengzhou, China

* xiaopengyang1233@163.com

Abstract

Background
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders. Recent studies have shown that mitochondrial dysfunction is a causative factor of AD. Drp1 (Dynamin-related protein 1), a regulator of mitochondrial fission, shows neuroprotective effects on Parkinson’s disease. In this study, we investigate the effect and mechanism of Drp1 on Aβ42 transgenic Drosophila.

Methods
Elav-gal4/UAS>Aβ42 transgenic Drosophila model was constructed using Elav-gal4 promoter. The effects of Drp1 on the lifespan, motor ability and neuronal degeneration of the transgenic Drosophila were explored by over-expressing Drp1 in the Aβ42 transgenic Drosophila. ATP levels in the brain tissues of Aβ42 transgenic Drosophila were detected using high performance liquid chromatography (HPLC).

Results
Exogenous expression of Drp1 promoted crawling ability, reduced the levels of ATP in Drosophila brain and suppressed the neuronal degeneration.

Conclusion
The protective effect of Drp1 on the Aβ42 transgenic Drosophila was achieved by protecting the mitochondrial function, suggesting that Drp1 may be a potential therapeutic strategies for AD.
Introduction

Alzheimer’s disease (AD), a degenerative disease of the central nervous system, is the most common type of neurodegenerative disorders [1–4]. AD is characterized by memory deficits and cognitive impairments. More than 36 million people older than 65 years were diagnosed as AD worldwide [1]. Amyloid β (Aβ) plays key roles in AD pathogenesis via regulating neuronal cell death [5, 6]. It was reported that the continuous production, degradation and the aggregation of amyloid beta-protein (Aβ) lead to AD [7]. Aggregation of beta amyloid (Aβ42) and tangles of neuronal fibers are the main pathological features [8,9]. However, the mechanisms driving the disease have not been completely understood.

Mitochondria are dynamic organelles with frequent fusion and fission [10]. A number of studies suggest mitochondrial dysfunction is a key causative factor of AD. Qi et al. and Xie et al. reported that inhibition of mitochondrial fission could protect the neuronal cells against neurotoxicity [11,12]. Therefore, exploring the regulators of mitochondrial dynamics may provide a novel therapeutic target for AD.

Dynamin-related protein 1 (Drp1), which belongs to the dynamin GTPase family, is a key regulator of mitochondrial fission [13,14]. Recent evidence suggested Drp1 played important roles in the neuroprotective effects [15,16]. Barsoum et al. and Gomez et al. reported that the hyperactivity of Drp1 induced by dopaminergic neurotoxins could promote neuronal cell death [17,18]. Moreover, in Phillip’s report, blocking the function of Drp1 in vivo either through genetic or small-molecule approach is neuroprotective in a mouse model with damage in the nigrostriatal pathway [19]. However, whether Drp1 provides neuroprotection in AD still remains unknown.

In this study, to explore whether Drp1 has a neuroprotective effect on AD, Drp1 was over-expressed in Aβ42 transgenic Drosophila nervous system using Elav-GALA4/UAS stains, and investigated whether the protective effects associated with the function of mitochondrial. Our results showed Drp1 may act as a potential therapeutic strategy for AD.

Materials and methods

Materials

458 strains of genotype P[w[+mW.hs] = GawB]Elav[C155], abbreviated as (Elav-GAL4 UAS-Drp1-DN), UAS-Drp1-DN DKVc-16 strains and P[UAS-APP.Aβ42.B] strains were purchased from Bloomington Drosophila Stock Center in USA. Aβ42 Drosophila primase and standard ATP solution were purchased from Tian Di Yang Biotechnology Company and Italy SANT S.R.L Company. BCA protein assay kit, hematoxylin and eosin (HE) staining kit were purchased from Beyotime Biotechnology Research Institute.

Chromatographic conditions

The mobile phase was prepared according to the appendix of Chinese pharmacopeia. Water: methanol (0.05 mol/L) was 92.5:7.5. 10.88 g KH₂PO₄ and 0.8 g NaOH were dissolved in 400 ml and 200 ml ultrapure water respectively. 121.6 ml NaOH solution, 400 ml KH₂PO₄ solution and 60 ml methanol solution were diluted with ultrapure water to 800 ml as phase solution. The phase solution was filtered using 0.45 μm filter and degassed in an ultrasonic bath. Flow rate: 1 ml/min, chromatographic column: Pak C184um PNova, detection wavelength: 259 nm.

Synthesis of nucleotide fragments

According to the cDNA sequence of Aβ42 in GenBank. The primers of Aβ42 gene and Aβ42-CpG fragment were artificially synthesized by Tian Di Yang Biotechnology Company.
The sequences of the forward and reversed primers for Aβ42 gene and CpG were 5’–GCAGATTCCGACATGACTCAG–3’ and 5’–GCCCACCATGAGTCCAAATGA–3’ respectively.

Construction of the Aβ42 transgenic *Drosophila* model

To construct the UAS-Aβ42arc/TM3 transgenic *Drosophila* with *W*, Elav-GAL4/FM genetic background, the W1118 virgin females and UAS-Aβ42Arc transgenic *Drosophila* were mated with Elav-GAL4 male respectively. Elav-W1118 and Elav-Aβ42 *Drosophila* were collected within 24 hours and killed after 25 days. Under the microscope, the *Drosophila* heads were cut by anatomical needle, and the brain tissues were extracted. Then, the expression of Aβ42 was determined by fluorescence PCR technique.

The life length test of *Drosophila*

The life length test of *Drosophila* was taken at 25°C. When entering eclosion period, the adult flies were killed. 200 newly emerged males were collected within 24 hours and fed with the fresh medium. The number of survival was recorded every 2 days. Each strain was divided into 5 groups and each group of 20 *Drosophila*. To determine whether the life length of *Drosophila* was shortened, the survival rate curve was done according to the average number of survival flies.

Crawling ability test

When entering eclosion period, 200 newly emerged males were collected within 24 hours and fed with the fresh medium. *Drosophila* creeping tubes were transparent plastic pipes with 30 cm in height, 2 cm in diameter, and 0.1 cm in thickness. The test was taken on 15th and 25th day. Each strain was divided into 5 groups and each group of 20 *Drosophila*. When the test was made, gently shake the tube body so that the *Drosophila* would drop into the bottom of the tubes. Due to the characteristics of negative chemotaxis, the fruit flies will leave the bottom of the tube to crawl. Record the numbers of *Drosophila* at different positions under 5 cm, between 5 and 10 cm and higher than 15 cm. Each group was tested 5 times, and the test interval was 5 minutes. The average number and standard deviation were calculated.

Detection of Aβ42 in brain

100 newly emerged males were collected within 24 hours and fed with fresh medium. The heads of 50 males drawn randomly were cut by dissecting needle after 25 days. The brain tissues were extracted under a microscope, then fixed in 10% buffered formalin and processed for paraffin sectioning. The sections were routinely dewaxed, hydrated, and stained with hematoxylin and eosin. After staining, the tissue sections were observed with the objective magnifications of 20X40.

Determination of the content of ATP in the brain of *Drosophila*

The brain tissues were extracted from 50 males drawn randomly on 25th day and ground in a mortar with liquid nitrogen and 200 μl of 0.4 mol/L HClO₄. Then, the grinding liquid was centrifuged at 3500 rpm for 15 min. KOH was added slowly to the supernatant to adjust the pH to neutral (supernatant: = 200:415 solution KOH ratio). The mixture was then centrifuged at 3500 rpm for 15 min. The supernatant was decanted and stored at -80°C. The level of ATP was determined by HPLC1100. 0.5, 1.0, 2.0, 4.0 and 6.0 ml of 0.1 mg/ml control ATPn and 1 ml internal standard solution were diluted into 10 ml, and then 10 μl of the diluent was injected into the chromatograph. The vertical coordinate indicated the ratio of the ATP to the internal
The role of Drp1 in the AD

standard peak and the horizontal coordinate indicated the ATP concentration. The regression equation is \(X = -0.31580 + 17.09515Y\), \(r = 0.9995\). The results showed good linearity when the concentration of ATP between 5 and 55 mg/L.

Statistical analysis

All results were expressed by mean ± standard deviation (X ± S). The paired t-test, one-way ANOVA, q test, and correlation analysis were used to compare the values from the experimental group and the controls using SPSS 17 statistical software. The difference was considered as significant when the p-value was less than 0.05.

Results

The characters of Elav-GAL4 system Aβ42 transgenic Drosophila

To determine the transgenic efficiency, the relative expression of Aβ42 was detected by fluorescent PCR. The value of the wild-type Elav-W1118 was 1, while that of Elav-Aβ42 was 200 (Fig 1A). According to the survival curve, the average life length of the wild-type Elav-W1118 and Elav-Aβ42 transgenic group were 72.6 days and 41.4 days, respectively. Over-expressing Drp1 extended the average life length of Elav-Aβ42 Drosophila from 41.4 days to 60.5 days (Fig 1B).

Crawling ability test of Elav-GAL4 system Aβ42 transgenic Drosophila

On the 15th day, the average numbers of Drosophila whose climbing heights within 5 cm of the wild-type Elav-W1118, model group Elav-Aβ42 and Elav- Aβ42/Drp1 group were 7.68, 15.58, 11.98 respectively. And on the 25th day, the numbers were 5.27, 11.01, and 10.68. On the 15th day, the average numbers of drosophila whose climbing heights above 15 cm for the wild-type Elav-W1118, model group Elav-Aβ42 and Elav-Aβ42/Drp1 group were 10.45, 1.86, 1.56. And the results showed good linearity when the concentration of ATP between 5 and 55 mg/L.

Fig 1. Elav-GAL4 system Aβ42 transgenic Drosophila. (a) The control group was wild-type Elav-W1118. The relative expression level of Aβ42 was increased about 200 times in Elav-Aβ42 Drosophila detecting by the fluorescent PCR. (b) The average lifetime of Elav-W1118 (72.6 days), Elav-Aβ42 transgenic (41.4 days) and Elav-Aβ42/Drp1 (60.5 days) were recorded as shown by the survival curves. After over-expressing Drp1 in Elav-Aβ42 transgenic Drosophila, it was found that the average life of Elav-Aβ42 / Drp1 was longer than that of Elav-Aβ42. The asterisks indicated the p value was lower than 0.05 when compared compared Elav-Aβ42 group to wild-type Elav-W1118 group.

https://doi.org/10.1371/journal.pone.0176183.g001
on the 25th day, the numbers became 5.27, 1.56 and 6.87. Thus, overexpression of Drp1 reduced the average numbers of *Drosophila* whose climbing heights within 5 cm and increased that whose climbing heights above 15 cm (Fig 2).

Detection of the neuronal degenerative level of Aβ42 transgenic *Drosophila*

Aβ42 amyloid fibrils in *Drosophila* brain tissues were detected by routine HE staining and observed with the Olympus microscope (objective: 20X, 40X). As shown in Fig 3, the exogenous expression of Drp1 in Elav-Aβ42 inhibited the neuronal degeneration.

The relative levels of ATP in Elav-GAL4 system Aβ42 transgenic *Drosophila*

The ATP levels in the head of *Drosophilas* were detected on the 25th day. The peak areas of the wild-type group Elav-W1118, model group Elav-Aβ42 and Elav-Aβ42/Drp1 group were 114.69 mAU’s, 88.61 mAU’s and 163.62 mAU’s respectively (Fig 4A). Similarly, the relative level of ATP level of Elav-Aβ42/Drp1 was 0.84, which was significantly increased compared to that of Elav-Aβ42 group (0.73) (Fig 4B).

Discussion

In this study, we investigated whether Drp1 contributes to the pathogenesis of AD. AD is the most common neurodegenerative disorder. Recently studies suggested that the continuous

![Fig 2. Crawling ability test.](https://doi.org/10.1371/journal.pone.0176183.g002)
production, degradation and the aggregation of amyloid beta-protein (Aβ) lead to AD. Aggregation of beta amyloid (Aβ42) and tangles of neuronal fibers are the main pathological features. In this study, we constructed an Aβ42 transgenic Drosophila model to explore the mechanisms driving the disease.

Although the pathogeny of AD remains unclear, studies have shown that mitochondrial dysfunction may be one of the causative factors [20,21]. Mitochondria are dynamic organelles. The excessive fusion and fission of mitochondria can lead to the change of size and shape of it. In the cell and mouse models of AD, mitochondrial fragmentation has been reported to contribute to the pathogenesis of AD [9,22].

Mitochondrial fission is controlled by the dynamin-related protein 1 (Drp1), which is a member of the dynamin family of large GTPase. Drp1 was reported to be involved in several important structural features of mitochondria, including shape, size, distribution, remodeling and the maintenance of mitochondria in mammalian cells [23]. Phosphorylation is the most common post-translational modification of Drp1, which regulates its activity. The functional roles of phosphorylation of serine 616 (S616) and serine 637 (S637) in Drp1 have been widely reported. Recently studies suggested important roles of Drp1 in the neuroprotective effects. In AD model mice, the phosphorylation level of Drp1 (Ser616) is significantly up-regulated in the brains cells [24,25]. Barsoum et al. and Gomez et al. also reported hyperactivity of Drp1

![Fig 3. Detection of the neuronal degeneration level.](https://doi.org/10.1371/journal.pone.0176183.g003)
The role of Drp1 in the AD

Fig 4. Relative level of ATP of the transgenic Elav-GAL4 system. (a) In the first 25 days, ATP level in Drosophila head was measured, ATP peak area of the wild-type Drosophila was 114.69 mAU*s; after Drp1 overexpressed in Elav-AB42 Drosophila, the peak area (163.62 mAU*s) was significantly higher than that of Elav-AB42 Drosophila (88.61 mAU*s). (b) Similarly, the relative average level of ATP for Elav-AB42/Drp1 Drosophila (0.84) was significantly higher than that of Drosophila Elav-AB42 (0.73). The asterisks indicated the p value was lower than 0.05 when compared Elav-AB42 group or Elav-AB42/Drp1 group to wild-type Elav-W1118 group. The triangle indicated that the p value was lower than 0.05 compared between Elav-AB42 group and Elav-AB42/Drp1 group.

https://doi.org/10.1371/journal.pone.0176183.g004

inducing by the dopaminergic neurotoxins could promote neuronal cell death [17,18]. However, whether Drp1 contributes to AD pathogenesis remain still unclear.

It was reported that Drp1 cooperates with Aβ to regulate neuronal damage in the AD patients. Manczak et al. found that Drp1 interacts with Aβ monomers and oligomers in AD patients and these abnormal interactions are increased with the disease progression [26]. Dah et al. reported Aβ could also activate Drp1 through sustained phosphorylation of Akt [8].
Thus, it is reasonable to suppose that Drp1-Aβ42 interaction is implicated in the regulatory mechanism of Drp1 in Aβ42 transgenic Drosophila.

In this study, we investigated the roles of Drp1 in regulating the pathogenesis of AD by using Aβ42 transgenic Drosophila. With Elav-GAL4/UAS promoter, Aβ42 protein was expressed in the Drosophila brain neurons. With exogenous expression of Drp1, we found the average life expectancy of Elav-Aβ42 extended to 60.5 days from 41.4 days. We also found that exogenous expression of Drp1 could significantly promote crawling ability and reduced the level of ATP in brain tissues. Moreover, neuronal degeneration was suppressed after Drp1 overexpression. These results suggested that exogenous expression of Drp1 had a neuroprotective effect on Aβ42 transgenic Drosophila models.

Conclusions
Taken together, our study showed that exogenous expression of Drp1 could promote crawling ability, reduced the level of ATP in Drosophila brain and suppressed neuronal degeneration, suggesting that Drp1 may be a potential therapeutic strategy for AD disease. We think our study was helpful to explore the pathogenesis of the central nervous system degenerative disease like AD.

Author Contributions

Conceptualization: FSL XPY.
Formal analysis: FSL CHS.
Investigation: FSL XPY CJC CHS.
Methodology: FSL XPY CJC.
Project administration: XPY.
Resources: XPY.
Supervision: XPY.
Validation: FSL XPY.
Visualization: FSL XPY CJC.
Writing – original draft: FSL CJC.
Writing – review & editing: FSL XPY CJC CHS.

References
1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503):2112–7. Epub 2005/12/20. PubMed Central PMCID: PMCPmc2850264. https://doi.org/10.1016/S0140-6736(05)67889-0 PMID: 16360788
2. Kandimalla RJ, Anand R, Veeramanikandan R, Wani WY, Prabhakar S, Grover VK, et al. CSF ubiquitin as a specific biomarker in Alzheimer’s disease. Current Alzheimer research. 2014; 11(4):340–8. Epub 2014/04/12. PMID: 24720893
3. Kandimalla RJ, Prabhakar S, Binukumar BK, Wani WY, Gupta N, Sharma DR, et al. Apo-Epsilon4 allele in conjunction with Abeta42 and tau in CSF: biomarker for Alzheimer’s disease. Current Alzheimer research. 2011; 8(2):187–96. Epub 2011/01/13. PMID: 21222696
4. Kandimalla RJ PS, Wani WY, Kaushal A, Gupta N, Sharma DR, Grover VK, Bhardwaj N, Jain K, Gill KD. CSF p-Tau levels in the prediction of Alzheimer’s disease. Biology open. 2013;BIO20135447.
5. Kim B, Park J, Chang KT, Lee DS. Peroxiredoxin 5 prevents amyloid-beta oligomer-induced neuronal cell death by inhibiting ERK-Drp1-mediated mitochondrial fragmentation. Free Radic Biol Med. 2016; 90:184–94. Epub 2015/11/20. https://doi.org/10.1016/j.freeradbiomed.2015.11.015 PMID: 26582373

6. Manczak M, Reddy PH. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: implications for mitochondrial dysfunction and neuronal damage. Human molecular genetics. 2012; 21(11):2538–47. Epub 2012/03/01. PubMed Central PMCID: PMC3439426. https://doi.org/10.1038/hmg.2012.72 PMID: 22367970

7. Jacobsen KT, Iverfeldt K. Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. Cellular and molecular life sciences: CMLS. 2009; 66(14):2299–318. Epub 2009/04/01. https://doi.org/10.1007/s00018-009-0020-8 PMID: 19333550

8. Kim DI, Lee KH, Gabr AA, Choi GE, Kim JS, Ko SH, et al. Aβ-Induced Drp1 phosphorylation through Akt activation promotes excessive mitochondrial fission leading to neuronal apoptosis. Biochimica Et Biophysica Acta. 2016; 1863(11):2820–34. https://doi.org/10.1016/j.bbamcr.2016.09.003 PMID: 27599716

9. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301Tau transgenic mice induced by Abeta 42 fibrils. Science (New York, NY). 2001; 293(5534):1491–5. Epub 2001/08/25.

10. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell. 2006; 125(7):1241–52. Epub 2006/07/04. https://doi.org/10.1016/j.cell.2006.06.010 PMID: 16814712

11. Qi X, Qvit N, Su YC, Mochly-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. Journal of Cell Science. 2013; 126( Pt 3):789–802. https://doi.org/10.1242/jcs.114439 PMID: 23239023

12. Xie N, Wang C, Lian Y, Wu C, Zhang H, Zhang Q. Inhibition of mitochondrial fission attenuates β-amyloid-induced microglia apoptosis. Neuroscience. 2014; 256:36–42. https://doi.org/10.1016/j.neuroscience.2013.10.011 PMID: 24144623

13. Bleazard W, McCaffrey JM, King EJ, Bale S, Mozdy A, Tieu Q, et al. The dynamin-related GTPase Dnm1 regulates mitochondrial fission in yeast. Nature Cell Biology. 1999; 1(5):298–304. https://doi.org/10.1038/13014 PMID: 10559943

14. Labrousse AM, Zappaterra MD, Rube DA, Bleik AMVD. C. elegans Dynamin-Related Protein DRP-1 Controls Severing of the Mitochondrial Outer Membrane. Molecular Cell. 1999; 4(5):815–26. PMID: 10619028

15. Kandimalla R, Manczak M, Fry D, Suneetha Y, Sesaki H, Reddy PH. Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Human molecular genetics. 2016; 25(22):4881–97. Epub 2017/02/09. https://doi.org/10.1038/hmg.2017.111 PMID: 28173111

16. Manczak M, Kandimalla R, Fry D, Sesaki H, Reddy PH. Protective effects of reduced dynamin-related protein 1 against amyloid-beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Human molecular genetics. 2016; 25(23):5148–66. Epub 2016/09/30. https://doi.org/10.1038/hmg.2016.286 PMID: 27677309

17. Barsoum MJ, Yuan H, Gerencser AA, Liot G, Kushnareva Y, Gräber S, et al. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. Embo Journal. 2006; 25(16):3900–11. https://doi.org/10.1038/sj.emboj.7601253 PMID: 16874299

18. Gomez-Lazaro M, Bonekamp NA, Galindo MF, Jordán J, Schrader M. 6-Hydroxydopamine (6-OHDA) induces Drp1-dependent mitochondrial fragmentation in SH-SY5Y cells. Free Radical Biology & Medicine. 2008; 44(11):1960–9.

19. Rappold PM, Cui M, Grima JC, Fan RZ, de Mesy Bentley KL, Chen L, et al. Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo. Nature Communications. 2014; 5:5244-. https://doi.org/10.1038/ncomms6244 PMID: 25370169

20. Verri M, Pastoris O, Dossena M, Aquilani R, Guerriero F, Cuzzoni G, et al. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer’s disease. International journal of immunopathology and pharmacology. 2012; 25(2):345–53. Epub 2012/06/16. https://doi.org/10.1177/091139041202500204 PMID: 22997066

21. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009; 29(28):9090–103. Epub 2009/07/17. PubMed Central PMCID: PMC2735241.

22. Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Searce-Levie K, et al. Nephrilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009; 29(7):1977–86. Epub 2009/02/21. PubMed Central PMCID: PMC2768427.
23. Filichia E, Hoffer B, Qi X, Luo Y. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson's disease model induced by MPTP. Scientific Reports. 2016; 6.

24. Kandimalla R, Reddy PH. Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis. Biochim Biophys Acta. 2016; 1862(4):814–28. Epub 2015/12/29. PubMed Central PMCID: PMCPmc5343673. https://doi.org/10.1016/j.bbadis.2015.12.018 PMID: 26708942

25. Yan J, Liu XH, Han MZ, Wang YM, Sun XL, Yu N, et al. Blockage of GSK3beta-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer's disease. Neurobiol Aging. 2015; 36(1):211–27. Epub 2014/09/07. https://doi.org/10.1016/j.neurobiolaging.2014.08.005 PMID: 25192600

26. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Human molecular genetics. 2011; 20(13):2495–509. Epub 2011/04/05. PubMed Central PMCID: PMCPmc3109997. https://doi.org/10.1093/hmg/ddr139 PMID: 21459773